Contemporary capabilities of CT texture analysis in the diagnosis of pheochromocytoma: associations with clinical, laboratory, and pathomorphological findings
- Authors: Tarbaeva N.V.1, Manaev A.V.1,2, Chevais A.1, Beltsevich D.G.1, Urusova L.S.1, Ebzeeva A.K.1, Roslyakova A.A.1, Mel'nichenko G.A.1, Mokrysheva N.G.1
-
Affiliations:
- Endocrinology Research Centre
- National Research Nuclear University MEPhI
- Issue: Vol 97, No 10 (2025): Issues of endocrinology
- Pages: 844-858
- Section: Original articles
- URL: https://journal-vniispk.ru/0040-3660/article/view/351371
- DOI: https://doi.org/10.26442/00403660.2025.10.203371
- ID: 351371
Cite item
Full Text
Abstract
Aim. To investigate the presence of statistically significant correlations between clinical and laboratory characteristics and features of contrast-enhanced computed tomography (CT) images, as well as to assess the possibility of predicting group classification according to the PASS scale based on clinical, laboratory, and contrast-enhanced CT imaging data.
Materials and methods. A retrospective analysis was performed on preoperative four-phase contrast-enhanced CT images of 230 patients with a pathomorphologically verified diagnosis of pheochromocytoma/paraganglioma. Clinical manifestations such as the presence and duration of arterial hypertension, carbohydrate metabolism disorders, and dyslipidemia were assessed. In the first stage, comparative and correlation analyses were conducted between hormonal parameters and contrast-enhanced CT data. In the second stage, based on morphological characteristics, patients were divided into two groups: with PASS scores <4 (n=155) and PASS scores ≥4 (n=56). Logistic regression analysis was conducted to evaluate the possibility of predicting group classification based on clinical, laboratory, and contrast-enhanced CT imaging data.
Results. Pheochromocytomas/paragangliomas with isolated normetanephrine secretion type accumulate significantly more contrast agent in the arterial and venous phases of the study (p<0.001) compared to other secretion types. Correlation analysis revealed statistically significant moderate positive correlations between blood normetanephrine levels and the volume of functioning tumor tissue without necrotic areas, as well as a moderate negative correlation between blood metanephrine levels and the maximum density in the venous phase, the percentage of venous contrast enhancement, and the 90th percentile of X-ray density of the functioning tumor tissue in the venous CT phase. A statistically significant association was also found between the presence/absence of necrosis and tumor size (p<0.001), as well as between structure and tumor size (p=0.004). No statistically significant correlations were identified between laboratory parameters, imaging data, and clinical manifestations (arterial hypertension, carbohydrate metabolism disorders, dyslipidemia, and carotid artery atherosclerosis). CT image characteristics allow for prediction of group classification according to the PASS scale with an AUC of 0.647 (95% confidence interval 0.471–0.797), sensitivity of 0.923 (0.727–1.000), specificity of 0.400 (0.250–0.548), PPV of 0.333 (0.176–0.500), and NPV of 0.941 (0.800–1.000).
Conclusion. Pheochromocytomas/paragangliomas are heterogeneous pathologies with diverse clinical, hormonal, and radiological characteristics that are associated with pathomorphological findings (PASS scale).
Full Text
##article.viewOnOriginalSite##About the authors
Natalia V. Tarbaeva
Endocrinology Research Centre
Author for correspondence.
Email: ntarbaeva@inbox.ru
ORCID iD: 0000-0001-7965-9454
канд. мед. наук, врач-рентгенолог, зав. отд-нием компьютерной и магнитно-резонансной томографии
Russian Federation, MoscowAlmaz V. Manaev
Endocrinology Research Centre; National Research Nuclear University MEPhI
Email: ntarbaeva@inbox.ru
ORCID iD: 0009-0003-8035-676X
мед. физик, аспирант
Russian Federation, Moscow; MoscowAnastassia Chevais
Endocrinology Research Centre
Email: ntarbaeva@inbox.ru
ORCID iD: 0000-0001-5592-4794
канд. мед. наук, врач-эндокринолог
Russian Federation, MoscowDmitry G. Beltsevich
Endocrinology Research Centre
Email: ntarbaeva@inbox.ru
ORCID iD: 0000-0001-7098-4584
д-р мед. наук, гл. науч. сотр.
Russian Federation, MoscowLiliya S. Urusova
Endocrinology Research Centre
Email: ntarbaeva@inbox.ru
ORCID iD: 0000-0001-6891-0009
д-р мед. наук, зав. отд-нием фундаментальной патоморфологии
Russian Federation, MoscowAminat K. Ebzeeva
Endocrinology Research Centre
Email: ntarbaeva@inbox.ru
ORCID iD: 0000-0002-3951-4338
клин. ординатор
Russian Federation, MoscowAnna A. Roslyakova
Endocrinology Research Centre
Email: ntarbaeva@inbox.ru
ORCID iD: 0000-0003-1857-5083
врач-эндокринолог
Russian Federation, MoscowGalina A. Mel'nichenko
Endocrinology Research Centre
Email: ntarbaeva@inbox.ru
ORCID iD: 0000-0002-5634-7877
акад. РАН, д-р мед. наук, проф., зав. каф. клинической эндокринологии Института высшего и дополнительного профессионального образования, зам. дир. Центра по научной работе
Russian Federation, MoscowNatalia G. Mokrysheva
Endocrinology Research Centre
Email: ntarbaeva@inbox.ru
ORCID iD: 0000-0002-9717-9742
акад. РАН, д-р мед. наук, проф., зав. каф. персонализированной и трансляционной медицины, дир.
Russian Federation, MoscowReferences
- Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-42. doi: 10.1210/jc.2014-1498
- Kiriakopoulos A, Giannakis P, Menenakos E. Pheochromocytoma: a changing perspective and current concepts. Ther Adv Endocrinol Metab. 2023;14:20420188231207544. doi: 10.1177/20420188231207544
- Lloyd R, Osamura R, Kloppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: International Agency for Research on Cancer, 2017.
- WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours. Vol. 8. 5th ed. Lyon: International Agency for Research on Cancer; 2022. Available at: https://tumourclassification.iarc.who.int. Accessed: 22.01.2025.
- Nölting S, Bechmann N, Taieb D, et al. Personalized management of pheochromocytoma and paraganglioma. Endocr Rev. 2022;43(2): 199-239. doi: 10.1210/endrev/bnab019
- Snezhkina A, Pavlov V, Dmitriev A, et al. Potential biomarkers of metastasizing paragangliomas and pheochromocytomas. Life (Basel). 2021;11(11):1179. doi: 10.3390/life11111179
- Thompson LD. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26(5):551-66. doi: 10.1097/00000478-200205000-00002
- Kimura N, Takayanagi R, Takizawa N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014;21:405-14. doi: 10.1530/ERC-13-0494
- Pierre C, Agopiantz M, Brunaud L, et al. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas. Virchows Arch. 2019;474(6):721-34. doi: 10.1007/s00428-019-02553-5
- Cho YY, Kwak MK, Lee SE, et al. A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma: ASES score. Surgery. 2018;164(3):511-17. doi: 10.1016/j.surg.2018.05.001
- Wachtel H, Hutchens T, Baraban E, et al. Predicting metastatic potential in pheochromocytoma and paraganglioma: a comparison of PASS and GAPP scoring systems. J Clin Endocrinol Metab. 2020;105(12): e4661-70. doi: 10.1210/clinem/dgaa608
- Stenman A, Zedenius J, Juhlin CC. The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas: a meta-analysis and systematic review. Cancers (Basel). 2019;11(2):225. doi: 10.3390/cancers11020225
- Aygun N, Uludag M. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings. Sisli Etfal Hastan Tip Bul. 2020;54(2):159-68. doi: 10.14744/SEMB.2020.18794
- Buitenwerf E, Korteweg T, Visser A, et al. Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: A multicenter study. Eur J Endocrinol. 2018;5(178):431-7. doi: 10.1530/EJE-18-0006
- Canu L, Van Hemert JAW, Kerstens MN, et al. CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. J Clin Endocrinol Metab. 2019;104(2):312-8. doi: 10.1210/jc.2018-01532
- Falhammar H, Kjellman M, Calissendorff J. Initial clinical presentation and spectrum of pheochromocytoma: A study of 94 cases from a single center. Endocr Connect. 2018;7:186-92. doi: 10.1530/EC-17-0321
- Guerrero MA, Schreinemakers JM, Vriens MR, et al. Clinical spectrum of pheochromocytoma. J Am Coll Surg. 2009;209:727-32. doi: 10.1016/j.jamcollsurg.2009.09.022
- Eisenhofer G, Lenders JW, Goldstein DS, et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem. 2005;51:735-44. doi: 10.1373/clinchem.2004.045484
- Ohara N, Uemura Y, Mezaki N, et al. Histopathological analysis of spontaneous large necrosis of adrenal pheochromocytoma manifested as acute attacks of alternating hypertension and hypotension: a case report. J Med Case Rep. 2016;10(1):279. doi: 10.1186/s13256-016-1068-3
- Mohamed HA, Aldakar MO, Habib N. Cardiogenic shock due to acute hemorrhagic necrosis of a pheochromocytoma: a case report and review of the literature. Can J Cardiol. 2003;19:573-6.
- Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007;92(10):3822-8. doi: 10.1210/jc.2007-0709
- Turkova H, Prodanov T, Maly M, et al. Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma/paraganglioma: an National Institutes of Health study. Endocr Pract. 2016;22(3):302-14. doi: 10.4158/EP15725.OR
- Юкина М.Ю., Трошина Е.А., Бельцевич Д.Г., и др. Феохромоцитома/параганглиома: клинико-генетические аспекты. Проблемы эндокринологии. 2013;59(3):19-26 [Iukina MIu, Troshina EA, Bel'tsevich DG, et al. Pheochromocytoma/paraganglioma: clinical and genetic aspects. Problems of Endocrinology. 2013;59(3):19-26 (in Russian)].
- Gild ML, Do K, Tsang VHM, et al. Pheochromocytoma in MEN2. Recent Results. Cancer Res. 2025;223:211-35. doi: 10.1007/978-3-031-80396-3_8
- Eisenhofer G, Walther MM, Huynh TT, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab. 2001;86(5):1999-2008. doi: 10.1210/jcem.86.5.7496
- De Leo A, Vara G, Paccapelo A, et al. Computerized tomography texture analysis of pheochromocytoma: relationship with hormonal and histopathological data. J Endocrinol Invest. 2022;45(10):1935-44. doi: 10.1007/s40618-022-01826-2
- Crimì F, Agostini E, Toniolo A, et al. CT texture analysis of adrenal pheochromocytomas: a pilot study. Curr Oncol. 2023;30(2):2169-77. doi: 10.3390/curroncol30020167
Supplementary files










